BioPark – bâtiment B
11 rue Watt
PathoQuest , a spin off from Institut Pasteur, was founded in 2010 by Professor Marc Eloit, D.V.M, Ph.D., a leading expert in the field of virology. Since its inception, PathoQuest has developed, validated, and patented sample preparation methods which allow a better detection of pathogens in biological samples. In parallel, PathoQuest has also developed a series of high performance IT tools and analytical software which enables a rapid, cost-effective, cloud based analysis of sequencing data.
Founder and CSO: Marc Eloit, DVM, PhD
CEO: Jean-François Brepson
CMO: Hélène Peyro-Saint-Paul
CTO: Charles Hébert
16 articles about PathoQuest
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods.
Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market
Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.
PathoQuest Receives GMP Certification for Its NGS-based Quality Control Testing Services of Biological Drugs
PathoQuest today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM).
PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory in Wayne, PA to expand its next-generation sequencing capabilities
PathoQuest announces the closing of an 8M euros financing series.
PathoQuest today announced the appointment of Christiane Honisch, Ph.D. as an independent member of the Company’s Board of Directors.
Company adds experienced executives to support the continued growth of Biologics Genomic Service and Clinical Diagnostics businesses which utilize PathoQuest’s proprietary Next-Generation Sequencing (NGS) based testing solution.
PathoQuest Announces Enrollment of First Patient in IDENTIFY, a Prospective Clinical Study Assessing the Medico-Economic Benefit of iDTECT™ Blood for the Diagnosis of Bloodstream Infection in Immunocompromised Patients
PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the initiation and enrollment of the first patient in a medico-economic study testing the company’s metagenomic iDTECT™ Blood test.
Charles River will provide clients access to PathoQuest’s NGS-based testing solutions
PathoQuest and Mayo Clinic Enter Into an Agreement to Conduct Study of iDTECT Blood in Patients With Febrile Neutropenia
PathoQuest announced that it will conduct research with Mayo Clinic to study the company’s proprietary iDTECT Blood test.
Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts.
PathoQuest Collaborating With Memorial Sloan Kettering Cancer Center to Study iDTECT Blood In Patients With Febrile Neutropenia
iDTECT Blood is the only CE-IVD NGS-based test which offers a culture-free, agnostic metagenomic approach to improving the breadth of pathogen detection.
PathoQuest Release: Proof-Of-Concept Study Published In Clinical Microbiology And Infection Reports The Benefit Of Pathoquest NGS-Based Metagenomics Test To Identify Clinically-Relevant Pathogens In Immunocompromised Patients Suspected Of Infection